GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE
The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders.
1 . A method of regulating smooth muscle tone in a subject, comprising the direct introduction into a sufficient number of smooth muscle cells of the subject a plasmid comprising a DNA sequence comprising a smooth muscle alpha actin (SMAA) promoter operably linked to a hSlo sequence encoding a maxi-K potassium channel protein and expression of the DNA sequence in said smooth muscle cells to regulate smooth muscle tone in the subject.
2 - 3 . (canceled)
4 . The method of claim 1 , wherein the smooth muscle cells are arterial smooth muscle cells, venous smooth muscle cells, or visceral smooth muscle cells.
5 . The method of claim 4 , wherein the smooth muscle cells are located in the bladder, blood vessel wall, gastrointestinal tract, bronchi of the lung, endopelvic fascia, penis, prostate gland, ureter, urethra, uterus, or vas deferens of the subject.
6 . The method of claim 4 , wherein the visceral smooth muscle cells are bladder smooth muscle cells, corporal smooth muscle cells, gastrointestinal smooth muscle cells, prostatic smooth muscle cells, or urethral smooth muscle cells.
7 . The method of claim 1 , wherein the DNA sequence is genomic DNA or cDNA.
8 . The method of claim 1 , wherein the potassium channel protein modulates relaxation of the smooth muscle.
9 . The method of claim 8 , wherein the potassium channel protein modulates relaxation of corporal smooth muscle.
10 - 19 . (canceled)
20 . The method of claim 1 , wherein the DNA sequence is introduced by naked DNA transfer.
21 . (canceled)
22 . The method of claim 1 , wherein the DNA sequence is introduced by means of direct injection into a smooth muscle wall.
23 . The method of claim 22 , wherein the smooth muscle is the bladder smooth muscle.
24 . (canceled)
25 . The method of claim 1 , wherein the subject has heightened contractility of a smooth muscle and regulation of the tone of the smooth muscle results in less heightened contractility of the smooth muscle in the subject.
26 . The method of claim 25 , wherein the smooth muscle cells are penile smooth muscle cells or bladder smooth muscle cells.
27 . The method of claim 1 , wherein the subject has an erectile dysfunction or a bladder dysfunction.
28 - 29 . (canceled)
30 . The method of claim 27 , wherein the erectile dysfunction results from incomplete relaxation of smooth muscle due to neurogenic dysfunction, arteriogenic dysfunction, and/or veno-occlusive dysfunction.
31 . (canceled)
32 . The method of claim 27 , wherein the bladder dysfunction results from bladder overactivity.
33 . The method of claim 27 , wherein the dysfunction is treated.
34 . (canceled)
35 . A method of treating erectile dysfunction in a subject, comprising the direct introduction into a sufficient number of corporal smooth muscle cells of the subject a plasmid comprising a DNA sequence comprising a smooth muscle alpha actin (SMAA) promoter operably linked to a hSlo sequence encoding a maxi-K potassium channel protein and expression of the DNA sequence in said corporal smooth muscle cells to enhance relaxation of corporal smooth muscle in the subject and thereby treat the subject's erectile dysfunction.
36 - 42 . (canceled)
43 . The method of claim 1 , wherein using the smooth muscle alpha actin (SMAA) promoter operably linked to a DNA sequence encoding the potassium channel protein is at least as effective in enhancing relaxation of the smooth muscle in a subject as using a viral promoter operably linked to the DNA sequence encoding the potassium channel protein.
44 . The method of claim 35 , wherein using the smooth muscle alpha actin (SMAA) promoter operably linked to a DNA sequence encoding the potassium channel protein that enhances relaxation of corporal smooth muscle is at least as effective in treating erectile dysfunction in a subject as using a viral promoter operably linked to the DNA sequence encoding the potassium channel protein.
45 . The method of claim 43 , wherein the viral promoter is a cytomegalovirus (CMV) promoter.